When a DPP4i is needed
TRAJENTA®: Unique convenience through one dose, once daily*1.
*Indicated for use in adult patients. TRAJENTA® is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.
†Combination therapies studied with linagliptin were: Linagliptin as add-on to metformin therapy; Linagliptin as add-on to a combination of metformin and sulphonylurea therapy; Linagliptin as add-on to a combination of metformin and empagliflozin; Linagliptin as add-on to insulin therapy.
‡No dose adjustment is necessary based on age. However, clinical experience in patients >80 years of age is limited and caution should be exercised when treating this population.
§Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.
BMI: Body mass index.